Invasive treatment
Invasive treatment has been studied in 1 paper since 2025: 1 observational study in people; 1 in the past year. The newest paper, Nov 24, 2025: “The effects of invasive treatment on patients with frailty and non-ST-segment elevation myocardial infarction”.
1 paper studies it3 findingsUpdated
“frail patients undergoing invasive treatment had a lower risk of recurrent MI (subdistribution hazard ratio [sHR], 0.681; 95% confidence interval [CI] 0.614-0.754; P < 0.001), all-cause mortality (adjusted hazard ratio [aHR], 0.447; 95% CI 0.410-0.488; P < 0.001) and MACE (aHR, 0.516; 95% CI 0.481-0.553; P < 0.001)”
None of its findings points the other way.
- 1 lab in 1 country
- Funder: Tianjin Health and Technology
- Humans1
What is Invasive treatment linked with?
3Studies link Invasive treatment with 3 measures, most often recurrent myocardial infarction (1 study), mortality (1) and major adverse cardiac events (1).
Recurrent myocardial infarction
downin humans1
1 study
Recurrent myocardial infarction
downin humans1
Invasive treatment is linked with a lower risk of recurrent myocardial infarction in NSTEMI patients with frailty (sHR 0.681, 95% CI 0.614-0.754, P < 0.001).
“frail patients undergoing invasive treatment had a lower risk of recurrent MI (subdistribution hazard ratio [sHR], 0.681; 95% confidence interval [CI] 0.614-0.754; P < 0.001)”
Humansin NSTEMI patients with frailty
Scientific reports
Mortality
downin humans1
1 study
Mortality
downin humans1
Invasive treatment is linked with a lower risk of mortality in NSTEMI patients with frailty (aHR 0.447, 95% CI 0.410-0.488, P < 0.001).
“all-cause mortality (adjusted hazard ratio [aHR], 0.447; 95% CI 0.410-0.488; P < 0.001)”
Humansin NSTEMI patients with frailty
Scientific reports
Major adverse cardiac events
downin humans1
1 study
Major adverse cardiac events
downin humans1
Invasive treatment is linked with a lower risk of major adverse cardiac events in NSTEMI patients with frailty (aHR 0.516, 95% CI 0.481-0.553, P < 0.001).
“frail patients undergoing invasive treatment had a lower risk of recurrent MI (subdistribution hazard ratio [sHR], 0.681; 95% confidence interval [CI] 0.614-0.754; P < 0.001), all-cause mortality (adjusted hazard ratio [aHR], 0.447; 95% CI 0.410-0.488; P < 0.001) and MACE (aHR, 0.516; 95% CI 0.481-0.553; P < 0.001)”
Humansin NSTEMI patients with frailty
Scientific reports